Janus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Down's syndrome Children with Down's syndrome (DS) have a 20-40-fold increased risk of acute myeloid leukemia (AML). The unique type of AML in DS is referred to as myeloid leukemia of Down's syndrome (ML-DS), 1 which is characterized by the frequent occurrence of acute megakaryoblastic leukemia (AMKL or FAB M7-like), a low diagnostic white blood cell count (WBC), young age and excellent outcome when reduced-intensity chemotherapy is applied. 2 Approximately 10% of the infants with DS exhibit a postnatal megakaryocytosis syndrome commonly called transient myeloproliferative disorder (TMD) or transient leukemia, which resolves spontaneously in the majority of the cases. Subsequently, approximately 20% of neonates with TMD develop ML-DS within the first 4 years of life.
Acquired mutations in the gene encoding for the major hematopoietic transcription factor GATA1 have been identified in leukemic blasts from virtually all patients with ML-DS and TMD, leading to the exclusive expression of a truncated GATA1 protein (GATA1s). Recently, two studies reported that GATA1s is insufficient to induce leukemia in the absence of other cooperating factors on the background of trisomy 21. 3, 4 Furthermore, little is known about the leukemogenesis of AMKL in children without DS (non-DS AMKL). In childhood non-DS AMKL, the t(1;22)(p13;q13) translocation encoding the OTT-MAL (RBM15-MKL1) fusion protein is frequently found.
In childhood AML, mutations in tyrosine kinases lead to dysregulated signal transduction activity, and have been implicated as frequent aberrations that confer a proliferative advantage to leukemic cells. 5 Using a proteomic approach, two groups recently identified several activated tyrosine kinases in the ML-DS cell line CMK and the AMKL cell line CHRF-288-11, lacking FLT3 or KIT mutations. 6, 7 Subsequent DNA sequence analysis identified the A572 V substitution in the pseudokinase domain of JAK3, and the T875N substitution in the JH1 domain of JAK2. DNA analysis of JAK3 in non-DS AMKL, ML-DS and TMD patients resulted in the identification of additional activating mutations located in the JH2 pseudokinase domain and in the FERM receptor binding domain. 6, 8 Constitutive activation of the tyrosine kinase and transformation of hematopoietic cells have been shown for several of the mutant alleles. 6, 7 As the JAK3 mutations were mainly found in samples from patients with ML-DS, we speculated that JAK3 mutations cooperate with other mutations such as GATA1s in the pathogenesis of ML-DS.
This prompted us to screen for JAK2 and JAK3 mutations in a cohort of 44 bone marrow or peripheral blood samples from 41 patients, including 14 patients with ML-DS, five patients with TMD, 13 patients with non-DS AMKL and nine healthy individuals with DS. The latter samples were obtained from sternal aspirates from children with DS without leukemia, undergoing elective cardiac surgery in Aarhus, Denmark, and were used to exclude germline mutations in DS children. From two patients with AMKL, and one patient with ML-DS, paired initial diagnosis-relapse samples were available. The ML-DS and TMD samples were obtained from different children (unpaired), and provided by two collaborative groups, that is, the AML-'Berlin-Frankfurt-Mü nster' Study Group (AML-BFM-SG, Hannover, Germany) and the Dutch Childhood Oncology Group (DCOG, The Hague, The Netherlands). Both study groups performed central review of the diagnosis, classification and clinical follow-up of the patients. All cell lines (CMK, HEL 92.1.7) were obtained from the 'German National Resource Centre for Biological Material (DSMZ)', and cultured under the recommended conditions. All investigations had been approved by the Institutional Review Board and Ethics Committee, and informed consent was obtained according to local law and regulations.
Low-density mononuclear cell populations of bone marrow or peripheral blood were isolated after density gradient centrifugation of the sample using Ficoll Isopaque. Genomic DNA was extracted using standard methods. For mutation detection, all exons encoding the JH2 pseudokinase domain of JAK3 plus exon 3 and JAK2 exons 12 and 20 were amplified, using nested PCR with two different primer sets. Bidirectional sequencing was performed on an ABI 377 sequencer using the BigDye terminator kit (Applied Biosystems Inc., Foster City, CA, USA). Bidirectional sequence traces were assembled and analyzed for mutations using Mutation Surveyor version 3.01 (SoftGenetics, State College, PA, USA).
The patient characteristics are provided in Table 1 . The median age of the TMD cohort was 3 days, for ML-DS children this was 1.8 years (range 0.9-3.8 years), and for non-DS AMKL 1.4 years (range 1.2-13.7 years). The median WBC count for TMD was 22.7 Â 10 9 /l, for DS-ML 13.8 Â 10 9 /l and for non-DS AMKL 12.6 Â 10 9 /l. Cytogenetic data were available in 5 out of 11 non-DS AMKL cases only, which showed no cases with t(1;22).
No JAK2 V617F , JAK2 T875N or other mutations were detected in any of the clinical samples. However, we identified the mutant JAK3 V722I allele in one out of 14 ML-DS patients, whereas none of the five patients with TMD, nor any of the 13 patients with non-DS AMKL harbored this particular mutation (Figure 1) . Moreover, none of the healthy DS children showed this particular mutation. One new heterozygous mutation (Jak3 M511I ) was identified in exon 10, in the same patient (ML-DS 8.1) who harbored the JAK3 V722I mutation in his leukemic cells. Of interest, this patient relapsed, and relapse material was also screened for JAK3 mutations. Both mutations were also present at relapse, suggesting clonal stability. No mutations in other tyrosine kinases (c-kit, FLT3, N-RAS, K-RAS) were detected in the sample taken at diagnosis (data not shown). We could not identify any other JAK3 mutation, including the previously Table 1 Characteristics of patients who were screened for JAK2 and JAK3 mutations Letters to the Editor described JAK3 P132T and the JAK3 A572V mutation, in any of the patient samples.
Taken together, no JAK2 mutations were found, but we did identify one ML-DS sample with two different JAK3 mutations, comprising 7% of the ML-DS samples tested in this study. This result is comparable with the recently published data by Kiyoi et al., 8 who found A573V and A593T substitutions in the JH2 pseudokinase domain of JAK3 in one out of 11 samples with ML-DS (9%). Kiyoi et al. could not verify any of the originally described mutations reported by Walters et al. 6 However, we did identify the JAK3 V722I mutation in our patient. Hence, the V722I substitution in JH2 pseudokinase domain of JAK3 might be a recurrent event in ML-DS. However, the role of this mutation remains elusive, as the same patient also showed an additional mutation in the same domain. This suggests that additional acquired mutations in this domain can provide a further growth advantage in the leukemic cells when compared to the JAK3 V722I mutation alone. Both mutations were also preserved in the relapse sample of this patient (ML-DS 8.2). The novelty of our study is that clinical data from the ML-DS patients were available. Interestingly, the patient with the JAK3 mutation was one out of two patients (patient ML-DS 2 also relapsed) who relapsed in this cohort of 14 ML-DS patients. Furthermore, the patient showed the highest diagnostic WBC (44.9 Â 10 9 /l) of all ML-DS patients. This may suggest that JAK3 mutations are associated with a more aggressive form of ML-DS, characterized by hyperleukocytosis at diagnosis and relapse. This hypothesis needs further validation in a prospective study. After reinduction therapy, the patient was successfully transplanted (autologous stem cell transplantation), and is still alive about 7 years post transplantation.
The role of the JAK3 A572V allele, which was first identified in the ML-DS cell line CMK, is still unclear. So far, two independent studies did not confirm this mutation in any of the tested 25 ML-DS patients. 8 Hence, this mutation might be unique to the cell line.
In contrast to the previous report, we could not detect mutations in the JAK2 or JAK3 genes in the TMD cohort, but numbers were small. Therefore, we cannot confirm the hypothesis that JAK mutations are an early event in the oncogenesis of ML-DS. Furthermore, we could not identify mutations of JAK2 or JAK3 in any of the patients with non-DS AMKL.
In mice, the truncated GATA1 protein leads to the hyperproliferation of a transient wave of megakaryocyte progenitors that The JAK3 JH2 domain was sequenced in 41 patients (14 ML-DS, 13 non-DS AMKL, five TMD and nine healthy individuals with DS), revealing a valine to isoleucine substitution at amino-acid position 722 in one patient with ML-DS (a). In the same sample, a methionine to isoleucine substitution at position 522 was detected, in addition to the V722I mutation (b).
Letters to the Editor appear in the yolk sac and the fetal liver without affecting differentiation. 4 However, additional genetic aberrations are needed to induce leukemia, as individuals with a germline splicing mutation of GATA1 only show a macrocytic anemia and neutropenia, but no leukemia. 3 Therefore, it needs to be tested whether JAK3 mutations can induce a leukemic phenotype in cooperation with GATA1s in a mouse model. As others and we could only verify these mutations in a small subgroup of ML-DS patients, we propose that other, yet unknown, cooperating factors on the background of trisomy 21 are required for oncogenesis. Further research needs to be carried out to identify these factors. In the past years it has become increasingly apparent that dysregulated transcriptional control is a key event in the pathogenesis of numerous examples of hematologic malignancy. So far, multiple recurrent chromosomal anomalies and gene rearrangements have been identified for most subsets of acute myeloid leukemia (AML). In a number of current pathogenesis models for AML and myelodysplastic syndromes (MDS) the recruitment of histone deacetylases (HDACs) is a crucial event and therefore the basis for innovative epigenetic treatment strategies. 1 HDACs comprise an increasing number of proteins, which may be divided into four major families on the basis of their sequence homology with their ancestor proteins in yeast: RPD3 (class I HDACs (HDAC1, 2, 3 and 8)), HDA1 (class II HDACs (4, 5, 6, 7, 9 and 10)), SIR2 (class III HDACs (sirtuins 1-7)) and HDAC11 (class IV HDAC). They play a key role in the regulation of transcription, cell cycle, differentiation and apoptosis and their dysregulation is involved in tumorigenesis. [2] [3] [4] HDACs have also been suggested to mediate the function of oncogenic translocation products in specific forms of leukemia 5 , in which chromosomal translocations create fusion proteins that block terminal differentiation of hematopoietic cells by recruiting multi-protein corepressor complexes, including class I HDACs, to target promoters.
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3,6-8 HDAC3 (5q31) and HDAC9 (7p21) are of special interest because of their gene loci in chromosomal regions, which have been described to be frequently altered preferentially in MDS and secondary AML.
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A single nucleotide polymorphism (SNP) is a difference between chromosomes in the base present at a particular site in the DNA sequence, which naturally occur within a population, presenting the most common type (90%) of genetic variation in humans.
12 SNPs are used for identification of inherited cancer susceptibility genes and there are great hopes that increasing knowledge of an individual's SNP genotype will provide additional information in the assessment of disease susceptibility and individualized treatment modalities. SNPs as disease markers are now the great hope of genetics.
In this context, it was the aim of our study to carry out SNP studies for HDACs that seem to play a decisive role in the pathogenesis of AML and which are typically located within chromosomal regions that are frequently altered in MDS and AML patients.
To identify SNPs in class I HDACs and HDAC9 we performed in silico analyses on three SNP databases; (1) the NIH Database of Single Nucleotide Polymorphisms (dbSNP), Bethesda (MD), National Center for Biotechnology Information, National Library of Medicine (dbSNP Build 125), 13 (2) HapMap 14 and (3) Applied Biosystems 15 ), which led to the identification of a total of 899 putative, validated and nonvalidated SNPs, which were divided into 883 intronic and 16 exonic, coding SNPs (cSNPs), whereupon the latter were further divided into six synonymous and 10 nonsynonymous SNPs.
The in silico analysis of the HapMap database revealed no validated nonsynonymous cSNPs in the analyzed HDACs. Via
